Ombitasvir/paritaprevir/r in hepatitis C: Indication of added benefit in certain patients
Thursday, May 28, 2015 - 10:00
in Health & Medicine
The new drug combination showed an advantage in three of a total of 16 patient groups, particularly regarding virologic response. The extent of added benefit remains unclear, however.